Tonix Pharmaceuticals (TNXP)
(Delayed Data from NSDQ)
$0.33 USD
+0.01 (3.89%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $0.34 +0.01 (1.95%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
TNXP 0.33 +0.01(3.89%)
Will TNXP be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for TNXP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for TNXP
Tonix Pharma’s Tonmya Shows Promise in Fibromyalgia Study
Tonix Pharmaceuticals presents additional efficacy data from RESILIENT
Tonix Pharma’s TNX-102 SL Shows Promise for PTSD Treatment
Tonix Pharmaceuticals announces publication on TNX-102 SL
Tonix Pharma: Anticipating Tonmya’s Impact on Fibromyalgia Treatment